DiCE Molecules SV, Inc.
279 E Grand Ave
South San Francisco
About DiCE Molecules SV, Inc.
At DiCE Molecules, we design and develop innovative therapies in immunology for patients with debilitating disease. Seeking to create a future where convenient oral medicines with biologic-like efficacy are available to patients with serious medical conditions, we are developing oral alternatives to medicines currently limited to injectable forms. We believe that such pills will be widely appreciated by patients and doctors alike, as they provide a lower bar to entry than biologics, and as oral medicines can easily be co-formulated with other efficacious drugs.
The combination of our core technology with additional, unique biophysical insights has enabled DiCE to target protein-protein interactions with small molecules. In doing so, DiCE has cracked open a previously intractable set of clinically validated therapeutic targets, including Interleukin-17 (IL-17). Our lead program – an orally bioavailable IL-17 antagonist for the treatment of psoriasis – is currently progressing through IND-enabling studies. In parallel, we continue to advance both partnered and internal pipeline drug discovery programs, providing a robust pre-clinical pipeline.
Located in South San Francisco, we've built a team of experienced industry professionals dedicated to innovation in immunology drug development.
5 articles with DiCE Molecules SV, Inc.
8/25/2021The current continues as investment dollars flow into the life sciences. Here’s an overview who is catching the drift this week.
DiCE Molecules today announced the completion of its $60 million Series C-1 financing.
Biopharma companies raking in the cash with investment rounds and IPO announcements.
Jake Simson, Ph.D., joins Board of Directors Financing proceeds will support the progression of the Company’s first-in-class, oral IL-17 antagonist into clinical trials and advancement of its PPI antagonist pipeline
A little less than two years after tying up a multi-billion deal with Sanofi, DiCE Molecules scored another collaborative deal.